LENVATINIB
Malignant Neoplasms of Thyroid and Other Endocrine Glands
M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Malignant Neoplasms of Thyroid and Other Endocrine Glands cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lanreotide Ipsen | Phase 3 | BB |
Pembrolizumab National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan M.D. Anderson Cancer Center | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
Eloxatin M.D. Anderson Cancer Center | Phase 2 | B |
View all 17 →
Same molecule, other indications
LENVATINIB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →